Table 1. Association of miR-370 expression and clinicopathologic characteristics in patients with breast cancer.
| Clinicopathologic feature | miR-370, No. (%) | p-value | |
|---|---|---|---|
| Low | High | ||
| Histological grade | 0.430 | ||
| Grade 1 & 2 | 16 (44.4) | 20 (55.6) | |
| Grade 3 | 14 (58.3) | 10 (41.7) | |
| Primary tumor size (cm) | 0.279 | ||
| <2 | 13 (61.9) | 8 (38.1) | |
| ≥2 | 17 (43.6) | 22 (56.4) | |
| LN metastasis | 0.009 | ||
| Not identified | 22 (66.7) | 11 (33.3) | |
| Present | 8 (29.6) | 19 (70.4) | |
| AJCC stage, 7th ed | 0.002 | ||
| I & II | 27 (64.3) | 15 (35.7) | |
| III & IV | 3 (16.7) | 15 (83.3) | |
| Lymphovascular invasion | 0.439 | ||
| Not identified | 17 (56.7) | 13 (43.3) | |
| Present | 13 (43.3) | 17 (56.7) | |
| Perineural invasion | 0.042 | ||
| Not identified | 28 (57.1) | 21 (42.9) | |
| Present | 2 (18.2) | 9 (81.8) | |
| Estrogen receptor | 0.792 | ||
| Negative | 13 (54.2) | 11 (45.8) | |
| Positive | 17 (47.2) | 19 (52.8) | |
| Progesterone receptor | 0.785 | ||
| Negative | 9 (45.0) | 11 (55.0) | |
| Positive | 21 (52.5) | 19 (47.5) | |
| HER2 amplification | 0.143 | ||
| Negative | 25 (56.8) | 19 (43.2) | |
| Positive | 5 (31.2) | 11 (68.8) | |
miR-370=microRNA-370; LN=lymph node; AJCC=American Joint Committee on Cancer; HER2=human epidermal growth factor receptor 2.